Cargando…

Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT

The purpose of this study was to evaluate the outcome after Radium-223-dichloride ((223)RaCl(2)) treatment of patients with skeletal metastases of castration resistant prostate cancer using whole-body (18)F-Fluoride PET/CT. Sodium (18)F-fluoride [(18)F]-NaF PET/CT was performed prior the treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kairemo, Kalevi, Joensuu, Timo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728467/ https://www.ncbi.nlm.nih.gov/pubmed/26854163 http://dx.doi.org/10.3390/diagnostics5040413

Ejemplares similares

Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics
por: Kairemo, Kalevi, et al.
Publicado: (2015)

Is interim (18)F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?
por: Etchebehere, Elba, et al.
Publicado: (2019)

A Retrospective Comparative Study of Sodium Fluoride (NaF-18)-PET/CT and Fluorocholine (F-18-CH) PET/CT in the Evaluation of Skeletal Metastases in Metastatic Prostate Cancer Using a Volumetric 3-D Radiomics Analysis
por: Kairemo, Kalevi, et al.
Publicado: (2020)

Preliminary Clinical Experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT Imaging in Prostate Cancer Patients
por: Kairemo, Kalevi, et al.
Publicado: (2014)

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

Radium 223 dichloride for prostate cancer treatment
por: Deshayes, Emmanuel, et al.
Publicado: (2017)

A Retrospective Comparative Study of Sodium Fluoride Na(18)F-PET/CT and (68)Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic Analysis
por: Kairemo, Kalevi, et al.
Publicado: (2022)

Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer
por: Renzulli, Joseph F, et al.
Publicado: (2015)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

Prognostic Value of (18)F-Choline PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223
por: Filippi, Luca, et al.
Publicado: (2020)

Interim and end-treatment (18)F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride
por: García Vicente, Ana María, et al.
Publicado: (2021)

Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA
por: Sartor, Oliver, et al.
Publicado: (2016)

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
por: Kairemo, Kalevi, et al.
Publicado: (2019)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study
por: Hyväkkä, Anniina, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain
por: Tirado Mercier, Eva, et al.
Publicado: (2018)

Analysis of Unusual Adverse Effects After Radium-223 Dichloride  Administration
por: Frantellizzi, Viviana, et al.
Publicado: (2020)

Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone
por: Takalkar, Amol, et al.
Publicado: (2014)

Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
por: Aprile, Carlo, et al.
Publicado: (2016)

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)

Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Yoshida, Keisuke, et al.
Publicado: (2016)

Factors Influencing Outcome Post–Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges
por: Bhoil, Amit, et al.
Publicado: (2022)

Radium-223 for the treatment of castration-resistant prostate cancer
por: El-Amm, Joelle, et al.
Publicado: (2015)

Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer
por: Hashimoto, Kohei, et al.
Publicado: (2020)

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2018)

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
por: Vidal, Monica, et al.
Publicado: (2020)

Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
por: Gayed, Isis, et al.
Publicado: (2018)

Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223
por: Bauckneht, Matteo, et al.
Publicado: (2019)

Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
por: von Eyben, Finn Edler, et al.
Publicado: (2017)

Radium-223 Chloride: A New Treatment Option for Metastatic Castration-Resistant Prostate Carcinoma
por: Pinto, Álvaro, et al.
Publicado: (2012)

Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer – role of radium-223
por: Mukherji, Deborah, et al.
Publicado: (2014)

Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
por: Prelaj, Arsela, et al.
Publicado: (2019)

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
por: Nilsson, S., et al.
Publicado: (2016)

Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases
por: Ogawa, Kazuma, et al.
Publicado: (2020)

Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model
por: Suominen, Mari I., et al.
Publicado: (2021)

Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_u2hl17uq1k4tubpn2b0ntbusa7